Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Typhoid fever Indication Strategy Report 2026: Salmonella Vi antigen, Trials and Deals
23 July 2026
2026 Typhoid fever strategy: epidemiology, Salmonella Vi antigen biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cholera Indication Strategy Report 2026: Cholera toxin, Trials and Deals
23 July 2026
2026 Cholera strategy: epidemiology, Cholera toxin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Bacterial vaginosis Indication Strategy Report 2026: Gardnerella vaginolysin, Trials and Deals
23 July 2026
2026 Bacterial vaginosis strategy: epidemiology, Gardnerella vaginolysin biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Trichomoniasis Indication Strategy Report 2026: Trichomonas AP65, Trials and Deals
23 July 2026
2026 Trichomoniasis strategy: epidemiology, Trichomonas AP65 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chlamydia infection Indication Strategy Report 2026: MOMP, Trials and Deals
23 July 2026
2026 Chlamydia infection strategy: epidemiology, MOMP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Syphilis Indication Strategy Report 2026: TpN47, Trials and Deals
23 July 2026
2026 Syphilis strategy: epidemiology, TpN47 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
Invasive group A streptococcal disease Indication Strategy Report 2026: Streptolysin O, Trials and Deals
23 July 2026
2026 Invasive group A streptococcal disease strategy: epidemiology, Streptolysin O biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pneumococcal disease Indication Strategy Report 2026: Pneumolysin, Trials and Deals
23 July 2026
2026 Pneumococcal disease strategy: epidemiology, Pneumolysin biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Meningococcal disease Indication Strategy Report 2026: Factor H binding protein, Trials and Deals
23 July 2026
2026 Meningococcal disease strategy: epidemiology, Factor H binding protein biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pertussis Indication Strategy Report 2026: Pertussis toxin, Trials and Deals
23 July 2026
2026 Pertussis strategy: epidemiology, Pertussis toxin biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Rubella Indication Strategy Report 2026: Rubella E1 protein, Trials and Deals
23 July 2026
2026 Rubella strategy: epidemiology, Rubella E1 protein biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Mumps Indication Strategy Report 2026: Mumps HN protein, Trials and Deals
23 July 2026
2026 Mumps strategy: epidemiology, Mumps HN protein biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…